Aerie Pharmaceuticals (AERI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2013 | 09-2013 | 06-2013 | 03-2013 | 12-2012 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -31,148 | -20,866 | -10,118 | -3,790 | -14,970 |
| Depreciation Amortization | 3,271 | 2,424 | 1,195 | 247 | 190 |
| Accounts payable and accrued liabilities | 2,045 | 1,025 | 459 | 852 | N/A |
| Other Working Capital | 1,529 | 1,007 | 457 | 795 | -1,260 |
| Other Operating Activity | 7,855 | 4,844 | 430 | -483 | 1,080 |
| Operating Cash Flow | $-16,448 | $-11,566 | $-7,577 | $-2,379 | $-14,960 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -63 | -28 | -17 | -6 | -50 |
| Investing Cash Flow | $-63 | $-28 | $-17 | $-6 | $-50 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 15,000 | 15,000 | 7,500 | 3,000 | N/A |
| Common Stock Issued | 71,870 | 1 | 1 | N/A | N/A |
| Dividend Paid | N/A | N/A | N/A | N/A | -130 |
| Other Financing Activity | -3,635 | -1,713 | -455 | 0 | 3,000 |
| Financing Cash Flow | $83,235 | $13,288 | $7,046 | $3,000 | $2,870 |
| Beginning Cash Position | 2,925 | 2,925 | 2,925 | 2,925 | 15,060 |
| End Cash Position | 69,649 | 4,619 | 2,377 | 3,540 | 2,920 |
| Net Cash Flow | $66,724 | $1,694 | $-548 | $615 | $-12,140 |
| Free Cash Flow | |||||
| Operating Cash Flow | -16,448 | -11,566 | -7,577 | -2,379 | -14,960 |
| Capital Expenditure | -63 | -28 | -17 | -6 | N/A |
| Free Cash Flow | -16,511 | -11,594 | -7,594 | -2,385 | -14,960 |